Biography
Hong Song received his MD from Tulane University School of Medicine and a Ph.D. in Chemical Engineering from Tulane University. He performed research in targeted radionuclide therapy as a postdoctoral fellow at the Johns Hopkins University. Following medical school, he joined Dual pathway Nuclear Medicine and Diagnostic Radiology residency at Stanford. His current research interests include PSMA PET in biochemically recurrent prostate cancer and DOTATATE PET in PRRT for neuroendocrine tumors.
View Full Biography
Professional Summary
Education & Certifications
- Medical Education: Tulane University School of Medicine (2016) LA
- Board Certification: American Board of Radiology, Diagnostic Radiology (2023)
- Board Certification: American Board of Nuclear Medicine, Nuclear Medicine (2022)
-
- Residency: Stanford University Radiology Residency (2022) CA
- Internship: Tulane University Internal Medicine Residency (2017) LA
Publications
-
Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management
Song, H., Mosci, C., Akatsu, H., Basina, M., Dosiou, C., & Iagaru, A. (2018). Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management. CLINICAL NUCLEAR MEDICINE, 43(10), 705–9. -
Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.
Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B., … Iagaru, A. (2019). Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD).
Song, H., Guja, K. E., & Iagaru, A. (2021). 18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD). Seminars in Nuclear Medicine. -
-
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., … Iagaru, A. (2021). PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
18F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.
Song, H., Iagaru, A., & Rowe, S. P. (2021). 18F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING
Baratto, L., Song, H., Duan, H., Moradi, F., Davidzon, G., & Iagaru, A. (2021). PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES
Song, H., Nguyen, J., Moradi, F., Aparici, C. M., Franc, B., Davidzon, G., & Iagaru, A. (2021). PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PSMA theragnostics for metastatic castration resistant prostate cancer.
Song, H., Guja, K. E., & Iagaru, A. (2022). PSMA theragnostics for metastatic castration resistant prostate cancer. Translational Oncology, 22, 101438. -
Biodistribution of a Mitochondrial Metabolic Tracer, [18F]F-AraG, in Healthy Volunteers.
Levi, J., Duan, H., Yaghoubi, S., Packiasamy, J., Huynh, L., Lam, T., … VanBrocklin, H. F. (2022). Biodistribution of a Mitochondrial Metabolic Tracer, [18F]F-AraG, in Healthy Volunteers. Molecular Imaging, 2022, 3667417. -
64Cu-DOTATATE Uptake in a Pulmonary Hamartoma.
Song, H., Guja, K. E., Yang, E. J., & Guo, H. H. (2023). 64Cu-DOTATATE Uptake in a Pulmonary Hamartoma. Clinical Nuclear Medicine, 48(1), 58–60. -
Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer
Duan, H., Song, H., Davidzon, G., Moradi, F., & Iagaru, A. (2022). Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors.
Levi, J., & Song, H. (2022). The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. Frontiers in Immunology, 13, 1113924. -
SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.
Song, H., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., … Iagaru, A. (2023). SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. European Journal of Nuclear Medicine and Molecular Imaging. -
Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., Song, H., & Iagaru, A. (2023). Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET. European Journal of Nuclear Medicine and Molecular Imaging. -
Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer
Song, H., Sjostrand, K., Duan, H., Ferri, V., Aparici, C. M., Davidzon, G., … Iagaru, A. (2023). Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy.
Handke, A., Kesch, C., Fendler, W. P., Telli, T., Liu, Y., Hakansson, A., … Seifert, R. (2023). Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy. Journal for Immunotherapy of Cancer, 11(10). -
68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.
Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A. M., … Iagaru, A. (2024). 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. The Lancet. Oncology. -
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., … Iagaru, A. (2024). Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. -
Alpha and Beta Radiation for Theragnostics.
Song, H., & Sgouros, G. (2024). Alpha and Beta Radiation for Theragnostics. PET Clinics. -
[18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue.
Levi, J., Guglielmetti, C., Henrich, T. J., Yoon, J. C., Gokhale, P. C., Reardon, D. A., … Chae, H.-D. D. (2024). [18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue. Communications Biology, 7(1), 793. -
Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT)
Bergstrom, C. P., Song, H., Ruiz, S. M., Chien, J., Moore, K., Parikh, D. A., … Khaki, A. R. (2024). Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
COMBAT: A study of <SUP>64</SUP>Cu-SAR-BBN and <SUP>67</SUP>Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.
Nordquist, L. T., Lengyelova, E., Almaguel, F., Mancini, B. R., Song, H., Armstrong, A. J., … Iagaru, A. (2024). COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
Weiss, V. L., Lee, T. H., Song, H., Kouo, T. S., Black, C. M., Sgouros, G., … Armstrong, T. D. (2012). Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells. PLOS ONE, 7(2), e31962. -
Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
Yoshida, T., Jin, K., Song, H., Park, S., Huso, D. L., Zhang, Z., … Sukumar, S. (2016). Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. Oncotarget, 7(22), 33306–15. -
Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.
Hobbs, R. F., Howell, R. W., Song, H., Baechler, S., & Sgouros, G. (2014). Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy. Radiation Research, 181(1), 90–8. -
Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.
Hobbs, R. F., Wahl, R. L., Frey, E. C., Kasamon, Y., Song, H., Huang, P., … Sgouros, G. (2013). Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 54(9), 1535–42. -
Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.
Song, H., Hedayati, M., Hobbs, R. F., Shao, C., Bruchertseifer, F., Morgenstern, A., … Sgouros, G. (2013). Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Molecular Cancer Therapeutics, 12(10), 2043–54. -
A nephron-based model of the kidneys for macro-to-micro a-particle dosimetry.
Hobbs, R. F., Song, H., Huso, D. L., Sundel, M. H., & Sgouros, G. (2012). A nephron-based model of the kidneys for macro-to-micro a-particle dosimetry. Physics in Medicine and Biology, 57(13), 4403–24. -
A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.
Hobbs, R. F., Song, H., Watchman, C. J., Bolch, W. E., Aksnes, A.-K. K., Ramdahl, T., … Sgouros, G. (2012). A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy. Physics in Medicine and Biology, 57(10), 3207–22. -
Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma.
Senthamizhchelvan, S., Hobbs, R. F., Song, H., Frey, E. C., Zhang, Z., Armour, E., … Sgouros, G. (2012). Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 53(2), 215–24. -
Modelling and dosimetry for alpha-particle therapy.
Sgouros, G., Hobbs, R. F., & Song, H. (2011). Modelling and dosimetry for alpha-particle therapy. Current Radiopharmaceuticals, 4(3), 261–5. -
Radioimmunotherapy of solid tumors: searching for the right target.
Song, H., & Sgouros, G. (2011). Radioimmunotherapy of solid tumors: searching for the right target. Current Drug Delivery, 8(1), 26–44. -
Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
Lingappa, M., Song, H., Thompson, S., Bruchertseifer, F., Morgenstern, A., & Sgouros, G. (2010). Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Research, 70(17), 6815–23. -
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., … Zanzonico, P. B. (2010). MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 51(2), 311–28. -
Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song, H., Hobbs, R. F., Vajravelu, R., Huso, D. L., Esaias, C., Apostolidis, C., … Sgouros, G. (2009). Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Research, 69(23), 8941–8. -
An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer.
Song, H., Shahverdi, K., Huso, D. L., Wang, Y., Fox, J. J., Hobbs, R. F., … Sgouros, G. (2008). An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 14(19), 6116–24. -
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.
Song, H., Shahverdi, K., Huso, D. L., Esaias, C., Fox, J., Liedy, A., … Sgouros, G. (2008). 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Research, 68(10), 3873–80. -
Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.
Kim, P. S., Armstrong, T. D., Song, H., Wolpoe, M. E., Weiss, V., Manning, E. A., … Jaffee, E. M. (2008). Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. The Journal of Clinical Investigation, 118(5), 1700–11. -
Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis.
Sgouros, G., & Song, H. (2008). Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis. Cancer Biotherapy & Radiopharmaceuticals, 23(1), 74–81. -
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.
Prideaux, A. R., Song, H., Hobbs, R. F., He, B., Frey, E. C., Ladenson, P. W., … Sgouros, G. (2007). Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 48(6), 1008–16. -
Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Song, H., Du, Y., Sgouros, G., Prideaux, A., Frey, E., & Wahl, R. L. (2007). Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 48(1), 150–7. -
Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song, H., He, B., Prideaux, A., Du, Y., Frey, E., Kasecamp, W., … Sgouros, G. (2006). Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 47(12), 1985–94. -
Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule.
Sgouros, G., Song, H., Ladenson, P. W., & Wahl, R. L. (2006). Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 47(12), 1977–84. -
Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody.
Emfietzoglou, D., Kostarelos, K., Papakostas, A., Yang, W.-H. H., Ballangrud, A., Song, H., & Sgouros, G. (2005). Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 46(1), 89–97. -
Extracellular matrix substrata alter adipocyte yield and lipogenesis in primary cultures of stromal-vascular cells from human adipose.
O'Connor, K. C., Song, H., Rosenzweig, N., & Jansen, D. A. (2003). Extracellular matrix substrata alter adipocyte yield and lipogenesis in primary cultures of stromal-vascular cells from human adipose. Biotechnology Letters, 25(23), 1967–72. -
Spatial composition of prostate cancer spheroids in mixed and static cultures.
Song, H., David, O., Clejan, S., Giordano, C. L., Pappas-Lebeau, H., Xu, L., & O'Connor, K. C. (2004). Spatial composition of prostate cancer spheroids in mixed and static cultures. Tissue Engineering, 10(7-8), 1266–76. -
Restructuring dynamics of DU 145 and LNCaP prostate cancer spheroids.
Song, H., Jain, S. K., Enmon, R. M., & O'Connor, K. C. (2004). Restructuring dynamics of DU 145 and LNCaP prostate cancer spheroids. In Vitro Cellular & Developmental Biology. Animal, 40(8-9), 262–7. -
Monte Carlo simulation of LNCaP human prostate cancer cell aggregation in liquid-overlay culture.
Song, H., O'Connor, K. C., Lacks, D. J., Enmon, R. M., & Jain, S. K. (2003). Monte Carlo simulation of LNCaP human prostate cancer cell aggregation in liquid-overlay culture. Biotechnology Progress, 19(6), 1742–9. -
Aggregation kinetics of well and poorly differentiated human prostate cancer cells.
Enmon, R. M., O'Connor, K. C., Song, H., Lacks, D. J., & Schwartz, D. K. (2002). Aggregation kinetics of well and poorly differentiated human prostate cancer cells. Biotechnology and Bioengineering, 80(5), 580–8.
-
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
- Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
- [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Practice Locations
SHC- Radiology (300P) Stanford, CA
Stanford, CAImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records